Quality of life and chronotherapy

REFERENCES

• Guyatt G.H., Feeny D.H., Patrick D.L. Measuring Health Related Quality of Life. Ann. Intern. Med. 1993; 118: 622–629
   PubMed Web of Science ®Google Scholar
• Testa M.A., Simonson D.C. Assessment of Quality of Life Outcomes. New Engl. J. Med. 1996; 334: 835–840
   PubMed Web of Science ®Google Scholar
• Muthny F.A., Koch U., Stumpt S. Quality of Life in Oncology Patients. Psychother. Psychosom. 1990; 54: 145–160
   PubMed Web of Science ®Google Scholar
• Aaronson N.K. Quality of Life: What Is It? How Should It Be Measured?. Oncology 1988; 2(5)69–74
   PubMedGoogle Scholar
• Aaronson N.K., Ahmedzai S., Bergman B., Monika B., Cull A., Duez N., Filiberti A., Flechtner H., Fleishman S.B., de Haes J.C.J.M., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P.B., Schraub S., Sneeuw K., Sullivan M., Tokeda F. The European Organization for the Research and Treatment of Cancer QLQ-C30: A Quality of Life Instrument for Use in International Clinical Trials in Oncology. J. Natl Cancer Inst. 1993; 85(5)365–376
   PubMed Web of Science ®Google Scholar
• Cella D.F., Cherin E.A. Quality of Life During and After Cancer Treatment. Compr. Ther. 1988; 4(5)69–75
   Google Scholar
• Steuart A.L., Ware J.E., Brook R.H. Advances in the Measurement of Functional Status: Construction of Aggregate Indexes. Med. Care 1981; 19: 473–488
   PubMedGoogle Scholar
• Schipper H., Clinh J., McMurrary A., Levitt M. Measuring the Quality of Life of Cancer Patients. The Functional Living Index—Cancer: Development and Validation. J. Clin. Oncol. 1984; 2: 472–483
   PubMed Web of Science ®Google Scholar
• Cella D.F. Measuring Quality of Life in Palliative Care. Semin. Oncol. 1995; 22((2) Suppl. 3)73–81
   PubMedGoogle Scholar
• Gill T.M., Feinstein A.R. A Critical Appraisal of the Quality of Quality-of-Life Measurements. J. Am. Med. Assoc. 1994; 272(8)619–626
   PubMed Web of Science ®Google Scholar
• Guyatt G., Walter S., Norman G. Measuring Change Over Time: Assessing the Usefulness of Evaluative Instruments. J. Chronic Dis. 1987; 40: 171–178
   PubMedGoogle Scholar
• Cella D.F., Bonomi A.E. Measuring Quality of Life: 1995 Update. Oncology 1995; 9(Suppl. 11)47–60
   PubMedGoogle Scholar
• Kornblith A.B., Holland J.C. Quality of Life. Memorial Sloan-Kettering Cancer Center, New York 1994; Vol. 1
   Google Scholar
• Cella D. Quality of Life. Psycho-oncology, J.C. Holland. Oxford University Press, New York 1998; 1135–1146
   Google Scholar
• Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: A Modular Supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for Use in Lung Cancer Clinical Trials. Eur. J. Cancer 1994; 30A: 635–642
   PubMed Web of Science ®Google Scholar
• Bjordal K., Kaasa S. Psychometric Validation of the EORTC Core Quality of Life Questionnaire, 30-Item Version and a Diagnosis-Specific Module for Head and Neck Cancer Patients. Acta Oncol. 1992; 31: 311–321
   PubMed Web of Science ®Google Scholar
• Sprangers M.A.G., Groenvold M., Arraras J.I., Franklin J., te Valde A., Muller M., Franzini L., Williams A., de Haes H.C., Hopwood P., Cull A., Aaronson N.K. The EORTC Breast Cancer-Specific Quality-of-Life Questionnaire Module: First Results from a Three-Country Field Study. J. Clin. Oncol. 1996; 14: 2756–2768
   PubMed Web of Science ®Google Scholar
• Johnson J.R., Temple R. Food and Drug Administration Requirements for Approval of New Anti-cancer Drugs. Cancer Treat. Rep. 1985; 69: 1155–1157
   PubMedGoogle Scholar
• Medical Research Council. Advice to Applicants of Clinical Trial Proposals, 1993.
   Google Scholar
• Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: Organization and Functions. Qual. Life Res. 1992; 1: 211–218
   PubMedGoogle Scholar
• Coates A., Thomson D., McLeod G.R., Hersey P., Gill P.G., Olver I.N., Hefford R., Lowenthal R.M., Beadle G., Walpole E. Prognostic Value of Quality of Life Scores in a Trial of Chemotherapy With or Without Interferon in Patients with Metastatic Malignant Melanoma. Eur. J. Cancer 1993; 29A: 1731–1734
   PubMed Web of Science ®Google Scholar
• Goodare H., Smith R. The Rights of Patients in Research. Br. Med. J. 1995; 310: 1277–1278
   PubMed Web of Science ®Google Scholar
• Gotay C.C., Korn E.L., McCabe M.S., Moore T.D., Cheson B.D. Quality-of- Life Assessment in Cancer Treatment Protocols: Research Issues in Protocol Development. J. Natl Cancer Inst. 1992; 84: 575–579
   PubMed Web of Science ®Google Scholar
• Bredart A., Razavi D. Preservation of Wellbeing in Cancer Patients: Role of Quality of Life and Satisfaction with Care Assessment. Oncol. Pract. 1997; 1: 16–17
   Google Scholar
• Razavi D., Delvaux N., Marchall S., Bredart A., Farvacques C., Paesmans M. The Effects of a 24 hour Psychological Training Program on Attitudes, Communication Skills and Occupational Stress in Oncology: A Randomised Study. Eur. J. Cancer 1993; 29A: 1858
   PubMed Web of Science ®Google Scholar
• Fayers P.M., Hopwood P., Horvey A., Girling D.S., Machin D., Stephens R. Quality of Life Assessment in Clinical Trials-Guidelines and a Checklist for Protocol Writers: the U.K. Medical Research Council Experience. Eur. J. Cancer 1997; 33(1)20–28
   PubMedGoogle Scholar
• Scheithauer W., Rosen H., Kornek G., Sebesta C., Depisch D. Randomised Comparison of Combination Chemotherapy Plus Supportive Care with Supportive Care Alone in Patients with Metastatic Colorectal Cancer. Br. Med. J. 1993; 306: 752–755
   PubMed Web of Science ®Google Scholar
• Expectancy or Primary Chemotherapy in Patients with Advanced Asymptomatic Colorectal Cancer: A Randomised Trial. J. Clin. Oncol. 1992; 10(6)904–911
   PubMedGoogle Scholar
• Glimelius B., Graf W., Hoffman K., Pahlman L., Sjoden P.O., Wennberg A. General Condition of Asymptomatic Patients with Advanced Colorectal Cancer Receiving Palliative Chemotherapy. A Longitudinal Study. Acta Oncol. 1992; 31(6)645–651
   PubMed Web of Science ®Google Scholar
• Glimelius B., Hoffman K., Graf W., Pahlman L., Sjoden P.O. Quality of Life During Chemotherapy in Patients with Symptomatic Advanced Colorectal Cancer. Cancer 1994; 73: 556–562
   PubMed Web of Science ®Google Scholar
• Cunningham D., Zalcberg J., Rath U., Oliver I., Van Cutsen E., Svensson C., Seitz J.F., Harper P., Kerr D., Perez-Manga G. Final Results of a Randomised Trial Comparing Tomudex (Raltitrexed) with 5-Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer. Ann. Oncol. 1996; 7: 961–965
   PubMed Web of Science ®Google Scholar
• Allen M., Cunningham D., Schmitt C. The Importance of Stabilization as an Endpoint in the Treatment of Metastatic Colorectal Carcinoma: Recent Quality of Life Studies. Anti-Cancer Drugs 1998; 9(9)783–790
   PubMedGoogle Scholar
• Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of Life and Survival with Continuous Ephatic-Artery Foxuridine Infusion for Colorectal Liver Metastases. Lancet 1994; 344: 1255–1260
   PubMed Web of Science ®Google Scholar
• Jonker D.J., Maroun J.A., Kocha W. Survival Benefit of Chemotherapy in Metastatic Colorectal Cancer: a Meta-analysis of Randomized Controlled Trials. Br. J. Cancer 2000; 82(11)1789–1794
   PubMedGoogle Scholar
• Cunningham D., Pyrhönen S., James R.D., Punt C.J., Hickish T.F., Heikkila R., Johannesen T.B., Starkhammar H., Topham C.A., Awad L., Jacques C., Herait P. Randomised Trial of Irinotecan Plus Supportive Care Versus Supportive Care Alone After Fluorouracil Failure for Patients with Metastatic Colorectal Cancer. Lancet 1998; 352(9138)1413–1418
   PubMed Web of Science ®Google Scholar
• Rougier P., Van Cutsen E., Bajetta E., Niederle N., Possinger K., Labianca R., Navaro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomised Trial of Irinotecan Versus Fluorouracil by Continuous Infusion After Fluorouracil Failure in Patients with Metastatic Colorectal Cancer. Lancet 1998; 352(9138)1407–1412
   PubMed Web of Science ®Google Scholar
• Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan Combined with Fluorouracil Compared with Fluorouracil Alone as First-Line Treatment for Metastatic Colorectal Cancer: a Multicentre Randomised Trial. Lancet 2000; 355(9209)1041–1047
   PubMed Web of Science ®Google Scholar
• Saltz L.B., Cox J.V., Blanche C., Rosen L.S., Feehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L. Irinotecan Plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. New Engl. J. Med. 2000; 343(13)905–914
   PubMed Web of Science ®Google Scholar
• De Gramont A., Figer M., Seymour M., Homerin M., Hmissi A., Cassidy S., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J. Clin. Oncol. 2000; 18(16)2938–2947
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., Biarnason G.A. Circadian Cancer Therapy. J. Clin. Oncol. 1993; 11: 1403–1407
   PubMed Web of Science ®Google Scholar
• Mormont M.C., Lévi F., Depres-Brummer P., Giacchetti S., Gruia G., Bleuzen P., Jasmin C., Misset J.L. Rest–Activity Circadian Rhythm: An Objective Measure for Performance Status (PS) and a Strong Indicator for Quality of Life (QL). Proc. Annu. Meet Am. Soc. Clin. Oncol. 1996; 15: A1633
   Google Scholar
• Mormont M.C., Waterhouse J., Bleuzen P., Giacchetti S., Jamia, Bogdan A., Lellouch S., Misset J.L., Touitou Y., Levi F. Marked 24-h Rest/Activity Rhythms Are Associated with Better Quality of Life, Better Response, and Longer Survival in Patients with Metastatic Colorectal Cancer and Good Performance Status. Clin. Cancer Res. 2000; 6: 3038–3045
   PubMed Web of Science ®Google Scholar
• Lévi F. Chronotherapy for Gastrointestinal Cancer. Curr. Opin. Oncol. 1996; 8: 334–338
   PubMedGoogle Scholar
• Lévi F., Soussan A., Adam R., Caussanel J.P., Metzger G., Jasmin C., Bismuth H., Smolesky M., Misset J.L. A Phase I–II Trial of Five-Day Continuous Intravenous Infusion of 5-Fluorouracil Delivered at Circadian Rhythm Modulated Rate in Patients with Metastatic Colorectal Cancer. J. Infus. Chemoth. 1995; 5(Suppl. 1)153–158
   PubMedGoogle Scholar
• Garufi C., Lévi F., Giunta S., Aschelter A.M., Pace R., Nisticò C., Terzoli E. Chronomodulated 5-day Infusion of Floxuridine and l-Folinic Acid in Patients with Advanced Malignancies: a Feasibility and Tolerability Study. J. Infus. Chemother. 1995; 5(Suppl. 1)134–137
   PubMedGoogle Scholar
• Garufi C., Lévi F., Aschelter A.M., Pacer R., Giunta S., Nisticò C., Gallà D.A., Silecchia G.F., Franchi F., Narduzzi C., Terzoli E. A Phase I Trial of 5-Day Chronomodulated Infusion of Fluorouracil and l-Folinic Acid in Patients with Metastatic Colorectal Cancer. Eur. J. Cancer 1997; 33: 1566–1571
   PubMed Web of Science ®Google Scholar
• Bertheault-Cvitkovic F., Jami A., Ithzaki M., Deprés Brummer P., Brienza S., Adam R., Kunstilinger F., Bismuth H., Misset J.L., Levi F. Biweekly Intensified Ambulatory Chronomodulated Chemotherapy with Oxaliplatin, 5-fluorouracil and Folinic Acid in Patients with Metastatic Colorectal Cancer. J. Clin. Oncol. 1996; 14: 2950–2958
   PubMed Web of Science ®Google Scholar
• Lévi F.A., Zidani R., Vannetzel J-M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L. Chronomodulated Versus Fixed Infusion Rate Delivery of Ambulatory Chemotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients with Colorectal Cancer Metastases: A Randomized Multi-institutional Trial. J. Natl Cancer Inst. 1994; 86(21)1608–1616
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Misset J.L. For the International Organization for Cancer Chronotherapy: Randomised Multicentre Trial of Chronotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid in Metastatic Colorectal Cancer. Lancet 1997; 350: 681–686
   PubMed Web of Science ®Google Scholar
• Levy N.B. Psychological Complications of Dialysis. Bull. Menninger Clin. 1984; 48(3)237–256
   PubMedGoogle Scholar
• Chiesa S., Gala C., Martini M., Pellegrini E., Pezzullo M. Studio Della QualitÀ di vita nei Trattamenti Alternativi Della Insufficienza Renale Cronica: Dialisi e Trapianto. Persona Umana e Ospedale, M. Frighi Cuzzolaro, G. Vetrone. Ies Mercuri, Rome 1986
   Google Scholar
• Pugliese P., Garufi C., Nisi E., Caruso A., Nisticò C., Giunta S., Giannarelli D., Terzoli E. Personality, Inner Experience and Compliance in Advanced Cancer Patients Treated with External Pumps. J. Infus. Chemother. 1995; 5(Suppl. 1)138–143
   PubMedGoogle Scholar
• Pugliese P., Nisi E., Garufi C., Caruso A., Terzoli E. Variabili Soggettive nei Protocolli. Il Paziente Oncologico Tra Realtà ed Emotività. Proceedings of the IV National Congress, E. Terzoli, A. Caruso. SIPO. 1995; 143–162
   Google Scholar
• Smit E.F., Willemse P.H.B., Sleifer D.Th., Uges D.R., Postmus P.E., Meijer S., Terheggen P.M., Mulder N.H., de Vriej E.G. Continuous Infusion Carboplatin on a 21-Day Schedule: a Phase I and Pharmacokinetic Study. J. Clin. Oncol. 1991; 9: 100–110
   PubMedGoogle Scholar
• Spielberger C.D., Gorsuch R.C., Luschene R.E. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA 1970
   Google Scholar
• Beck A.T., Ward C.H., Mendelson M. An Inventory for Measuring Depression. Arch. Gen. Psychiatry 1961; 41: 561–571
   Web of Science ®Google Scholar
• Greer S., Moorey S., Watson M. Patient's Adjustment to Cancer The Mental Adjustment to Cancer (M.A.C.) Scale Vs Clinical Ratings. J. Psychosom. Res. 1989; 33: 373–377
   PubMed Web of Science ®Google Scholar
• Zigmond S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983; 67: 361–370
   PubMed Web of Science ®Google Scholar
• Pugliese P., Nisi E., Garufi C., Terzoli E. The Medical Team and the Psychological Containment During Chemotherapy: the Patient Point of View. Psycho-Oncology 1996; 5(A2)188
   Google Scholar
• Second Strategy Meeting of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC). Relevance of Biological Rhythms for Quality of Life and Survival in Cancer Patients, 21–23 September 2000, St. Raphael (France), 2000.
   Google Scholar
• Pugliese P., Garufi C., Perrone M., D'Attino R.M., Aschelter A.M., Zappalà A.R., Antonini C.G.C., Giannarelli D., Cosimelli M., Terzoli E. Quality of Life (QoL) Evaluation During Infusional Chronotherapy (Chrono) in Advanced Colorectal Cancer (ACC) Patients (Pts): Correlation with Clinical Parameters. Proc. Am. Soc. Clin. Oncol. 2000; 19: A1098
   Google Scholar
• Garufi C., Brienza S., Pugliese P., Aschelter A.M., Bensmaine ., Bertheault-Lvitkovic F., Nisticò C., Giunta S., Caterino M., Giannarelli D., Cosimelli M., LevÌ F., Terzoli E. Overcoming Resistence to Chronomodulated 5-Fluorouracil and Folinic Acid by the Addition of Chronomodulated Oxaliplatin in Advanced Colorectal Cancer Patients. Anti-Cancer Drugs 2000; 11: 495–501
   PubMedGoogle Scholar
• Seymour M.T., Tabah-Fish I., Homerin M. Quality of Life in Advanced Colorectal Cancer: a Comparison of QoL During Bolus Plus Infusion 5-FU/Leucovorin With or Without Oxaliplatin. Proc. Soc. Ann. Clin. Oncol. 1999; 18: A901
   Google Scholar
• Garufi C., Aschelter A.M., Zappalà A., D'Attino R.M., Antonini C.G.C., Rosati N., Nisticò C., Cosimelli M., Giannarelli D., Terzoli E. Chronomodulated (Chrono) Infusion of 5-Fluorouracil (5-FU) and l-Folinic Acid (FA) in 91 Patients (pts) with Metastatic Colorectal Cancer: the Regina Elena Cancer Institute Experience. Eur. J. Cancer 1999; 35(4)A221
   Google Scholar
• Garufi C., Dogliotti L., D'Attino R.M., Tampellini M., Aschelter A.M., Pugliese P., Perrone M., Nisticò C., Comis S., Terzoli E. Irinotecan (CPT-11) and Chronomodulated Infusion of 5-Fluorouracil and Folinic Acid (CPT-11/ff16) for Patients with Advanced Colorectal Cancer: a Phase I Study. Cancer 2001; 91(4)712–720
   PubMedGoogle Scholar
• Antonini C.G.C., Garufi C., Zappalà A., Ascheletr A.M., D'Attino R.M., Pugliese P., Perrone M., Nisticò C., Giunta S., Caterino M., Ricciotti A., Cosimelli M., Terzoli E. Mitomycin-C (MMC) Plus Chronomodulated Infusion of 5-Fluoro-uracil (5-FU) and Folinic Acid (FA) (MMC/FF5-16) in 46 Advanced Colorectal Cancer (ACC) Patients (PTS). Ann. Oncol. 2000; 11(Suppl. 2)AH2
   Google Scholar
• Bertolini R., Focan C., Bartholome F., Baro V. Comparative Psychological Aspects of two Different Types of Chemotherapy Administration (Chronotherapy vs. Traditional Chemotherapy) on Quality of Life of Cancer Patients ad Advanced Stage. In Vivo 1995; 9: 583–588
   PubMedGoogle Scholar
• Bertolini R. Détresse émotionnelle (Anxiété, Dépression), Adaptations Cognitives et Comportementales et Qualité de vie Chez des Patients Cancéreux Recevant un Traitement Chimiothérapique via une Pompe Multicanaux, Programmable et Portable: Informatio Informations Sensorielles/Pro-cédurales et Conseils en vue de Diminuer L'anxiété Précédant le Traitement. Mémoire de Licence en Psychologie Université de Liège, Liège 1993; 139
   Google Scholar
• Pugliese P., Perrone M., Garufi C., Nisi E., Aschelter A.M., Zappalà A., Antonini C.G., Terzoli E. A Preventive Psychological Crisis Intervention (PPCI) to Improve the Qualità of Life In Reply to: Advanced Colorectal Cancer (ACC) Patients Submitted to Chronotherapy. Ann. Oncol. 2000; 11(Suppl. 2)AH48
   Google Scholar